LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

Search

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

52.33 0.62

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

51.91

Max

52.62

Belangrijke statistieken

By Trading Economics

Inkomsten

-19M

118M

Verkoop

-33M

265M

K/W

Sectorgemiddelde

17.707

56.602

EPS

1.11

Winstmarge

44.588

Werknemers

350

EBITDA

-34M

169M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.8% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

757M

8.2B

Vorige openingsprijs

51.71

Vorige sluitingsprijs

52.33

Nieuwssentiment

By Acuity

34%

66%

86 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mrt 2025, 19:42 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mrt 2025, 10:30 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1 nov 2024, 11:30 UTC

Top Nieuws

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

23.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 64.4 USD  23.8%

Hoogste 79 USD

Laagste 47 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

5

Buy

4

Hold

1

Sell

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

86 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.